Stocktoria

Scholar Rock Holding Corp SRRK

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2018-05-24 · LEI

Scholar Rock Holding Corp financials (annual)

Revenue
$0 $20.5M $15.4M $18.8M $33.2M $0 201720182019202020212022202320242025
Net income
-$25.0M -$49.3M -$51.0M -$86.5M -$131.8M -$134.5M -$165.8M -$246.3M -$377.9M 201720182019202020212022202320242025
Free cash flow
-$22.1M $23.1M -$66.2M -$64.4M -$132.0M -$133.8M -$145.3M -$201.0M -$300.6M 201720182019202020212022202320242025

Bars are annual figures from 2017 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue$0$33.2M$18.8M$15.4M$20.5M$0
R&D expense$208.4M$184.6M$121.9M$124.4M$108.5M$74.1M$54.2M$36.3M$19.9M
Operating income-$384.6M-$252.1M-$171.3M-$134.4M-$129.9M-$86.9M-$54.5M-$50.7M-$25.0M
Net income-$377.9M-$246.3M-$165.8M-$134.5M-$131.8M-$86.5M-$51.0M-$49.3M-$25.0M
EPS (diluted)$-3.29$-2.47$-1.99$-2.26$-3.59$-2.81
Operating cash flow-$300.0M-$200.9M-$145.2M-$132.7M-$126.8M-$60.3M-$63.1M$24.6M-$21.7M
Free cash flow-$300.6M-$201.0M-$145.3M-$133.8M-$132.0M-$64.4M-$66.2M$23.1M-$22.1M
Cash & equivalents$323.5M$177.9M$101.9M$103.3M$212.8M$160.4M$36.3M$115.1M$56.5M
Total assets$404.3M$474.9M$311.0M$358.2M$304.4M$388.3M$196.4M$181.3M$61.6M
Total liabilities$158.8M$106.3M$85.8M$97.9M$132.4M$127.5M$83.5M$74.7M$5.9M
Shareholders' equity$245.5M$368.6M$225.2M$260.2M$172.1M$260.8M$112.9M$106.6M-$53.5M

Growth · year-over-year

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue growth+76.4%+22.2%-24.8%
Free cash flow growth-387.0%

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.